PuSH - Publikationsserver des Helmholtz Zentrums München

Penkert, J.* ; Schmidt, G.* ; Hofmann, W.* ; Schubert, S.* ; Schieck, M.* ; Auber, B.* ; Ripperger, T.* ; Hackmann, K.* ; Sturm, M.* ; Prokisch, H. ; Hille-Betz, U.* ; Mark, D.* ; Illig, T.* ; Schlegelberger, B.* ; Steinemann, D.*

Breast cancer patients suggestive of Li-Fraumeni syndrome: Mutational spectrum, candidate genes, and unexplained heredity.

Breast Cancer Res. 20:87 (2018)
Verlagsversion DOI PMC
Open Access Gold
Background: Breast cancer is the most prevalent tumor entity in Li-Fraumeni syndrome. Up to 80% of individuals with a Li-Fraumeni-like phenotype do not harbor detectable causative germline TP53 variants. Yet, no systematic panel analyses for a wide range of cancer predisposition genes have been conducted on cohorts of women with breast cancer fulfilling Li-Fraumeni(-like) clinical diagnostic criteria. Methods: To specifically help explain the diagnostic gap of TP53 wild-type Li-Fraumeni(-like) breast cancer cases, we performed array-based CGH (comparative genomic hybridization) and panel-based sequencing of 94 cancer predisposition genes on 83 breast cancer patients suggestive of Li-Fraumeni syndrome who had previously had negative test results for causative BRCA1, BRCA2, and TP53 germline variants. Results: We identified 13 pathogenic or likely pathogenic germline variants in ten patients and in nine genes, including four copy number aberrations and nine single-nucleotide variants or small indels. Three patients presented as double-mutation carriers involving two different genes each. In five patients (5 of 83; 6% of cohort), we detected causative pathogenic variants in established hereditary breast cancer susceptibility genes (i.e., PALB2, CHEK2, ATM). Five further patients (5 of 83; 6% of cohort) were found to harbor pathogenic variants in genes lacking a firm association with breast cancer susceptibility to date (i.e., Fanconi pathway genes, RECQ family genes, CDKN2A/p14ARF, and RUNX1). Conclusions: Our study details the mutational spectrum in breast cancer patients suggestive of Li-Fraumeni syndrome and indicates the need for intensified research on monoallelic variants in Fanconi pathway and RECQ family genes. Notably, this study further reveals a large portion of still unexplained Li-Fraumeni(-like) cases, warranting comprehensive investigation of recently described candidate genes as well as noncoding regions of the TP53 gene in patients with Li-Fraumeni(-like) syndrome lacking TP53 variants in coding regions.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Breast Cancer ; Cdkn2a ; Fanca ; Fanconi Pathway ; Hboc ; Li-fraumeni Syndrome ; Li-fraumeni-like Syndrome ; Recq Family ; Tp53; Integrative Genomics Viewer; P53 Germline Mutations; Ovarian-cancer; Ataxia-telangiectasia; Families; Atm; Predisposition; Criteria; Variants; Protein
ISSN (print) / ISBN 1465-5411
e-ISSN 1465-542X
Zeitschrift Breast Cancer Research
Quellenangaben Band: 20, Heft: 1, Seiten: , Artikelnummer: 87 Supplement: ,
Verlag BioMed Central
Verlagsort Campus, 4 Crinan St, London N1 9xw, England
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Human Genetics (IHG)